HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
24 Settembre 2024 - 2:31PM
Business Wire
Industry Leader, Former Head of Data Science at
Verily (Google Life Sciences) and Globally Respected Authority on
Artificial Intelligence (AI) Applications in Biosensor
Technologies
Dr. Myers to Drive Innovation and Strategic
Growth as HeartBeam Advances and Expands its AI Capabilities
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology
company focused on transforming cardiac care by providing powerful
cardiac insights wherever the patient is, announced the appointment
of Lance Myers, PhD, a pioneer in digital health data analytics and
body-worn biosensor technologies, as Chief Artificial Intelligence
(AI) Scientist. In this newly created position, Dr. Myers will play
a pivotal role in guiding how AI is applied to the Company’s core
technology.
“We’ve made tremendous progress with our deep learning approach
with data demonstrating that combining HeartBeam AI with a
vector-based approach delivered equivalent performance to a 12-lead
ECG and greatly improved detection of atrial flutter over a
single-lead ECG,” said Branislav Vajdic, PhD, Chief Executive
Officer and Founder of HeartBeam. “As we enter the next phase of
development, we’re pleased to have an industry leader of Lance’s
caliber join our team. His insights and expertise will have an
immediate impact as we strive to transform cardiac care by
harnessing the power of AI with our data-rich technology.”
HeartBeam’s core technology captures the heart’s electrical
signals from three dimensions to provide total heart intelligence.
The Company’s first application of the technology is a cable-free,
credit card-sized device that is designed to be capable of
synthesizing a 12-lead ECG. The HeartBeam system is currently under
review with the FDA and is the foundational 510(k) submission upon
which future submissions will be based. The Company has 13 issued
US patents and 4 issued international patents supporting the
underlying technology.
By leveraging AI to analyze the data-rich signals, the Company
believes it will be able to improve diagnostic accuracy and unlock
a more personalized approach to cardiac care for patients. As a
patient uses the HeartBeam device over time, there will be a series
of ECG readings. The Company aims to leverage AI to analyze the
data to provide a longitudinal view of the patient’s cardiac status
and move beyond today’s 12-lead ECGs, which typically only provide
a snapshot in time. HeartBeam AI is currently under
development.
“Being appointed as Chief AI Scientist is both an honor and an
exciting challenge. The HeartBeam technology, when combined with
advanced AI, has tremendous potential to unlock and deliver
groundbreaking cardiac management solutions spanning diagnostics,
screening, predictive analytics and closed-loop patient management
– where detection, intervention and real-time measurement
continually refine and optimize treatment outcomes. By leveraging
longitudinal trends and increasing user data, we can uncover new
insights, pushing the boundaries of AI in cardiac care and bringing
transformative advancements to patients,” commented Dr. Myers.
Most recently, Dr. Myers served as AI Advisor to HeartBeam.
Previously, he was the Head of Cardiovascular Devices at Verily
Life Sciences (formerly Google Life Sciences), where he led a team
developing a novel heart failure monitoring solution. Prior to
that, he was the Head of Data Science at Verily and built a
high-performance AI organization with teams in computational
biology, medical device and biosensor algorithms, digital
biomarkers, health informatics and digital pathology. He has also
held leadership roles at XAI.health, Sentrian, VivoSense, Boston
Neurosciences and Vivometrics. He currently serves as a board
member for VivoSense and is on the scientific advisory boards of
Acorai, XAI.health and Bryte. Dr. Myers received his PhD in
Biomedical Engineering from the University of Cape Town in South
Africa.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
dedicated to transforming cardiac care by providing powerful
cardiac insights wherever the patient is. The Company is creating
the first ever cable-free 12-lead ECG capable of capturing the
heart’s electrical signals from three dimensions. This platform
technology is designed to be used in portable devices that can be
used wherever the patient is to deliver actionable heart
intelligence. Physicians will be able to identify cardiac health
trends and acute conditions and direct patients to the appropriate
care – all outside of a medical facility, thus redefining the
future of cardiac health management. The Company holds 13 US and 4
international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240924390170/en/
Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
Media Contact:media@heartbeam.com
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Dic 2023 a Dic 2024